EntryPoint Capital’s Arbutus Biopharma ABUS Stock Holding History

EntryPoint Capital’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$134K	Sell	27,940 -82,183	-75%	-$361K	0.03%	730
2026 Q1	$496K	Buy	110,123 +34,516	+46%	+$151K	0.15%	255
2025 Q4	$364K	Buy	75,607 +46,743	+162%	+$210K	0.14%	282
2025 Q3	$131K	Sell	28,864 -32,241	-53%	-$118K	0.05%	605
2025 Q2	$189K	Buy	61,105 +42,375	+226%	+$141K	0.09%	496
2025 Q1	$65.4K	Buy	+18,730	New	+$62.5K	0.03%	638

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EntryPoint Capital's ABUS Position: Q2 2026 in Review

EntryPoint Capital reduced its Arbutus Biopharma (ABUS) stake by 75% in Q2 2026, selling an estimated $361K and leaving 27,940 shares worth $134K. The position accounts for 0.03% of the portfolio, ranked #730.

EntryPoint Capital first reported a position in ABUS in Q1 2025 and has held it in 6 quarters since. The position peaked at $496K in Q1 2026. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

EntryPoint Capital held 27,940 shares of Arbutus Biopharma worth $134K as of Q2 2026.
EntryPoint Capital sold 82,183 Arbutus Biopharma shares in Q2 2026, an estimated $361K.
Arbutus Biopharma made up 0.03% of EntryPoint Capital's portfolio in Q2 2026, its #730 holding.
EntryPoint Capital first reported a position in Arbutus Biopharma in Q1 2025 and has held it in 6 quarters since.
EntryPoint Capital's Arbutus Biopharma position peaked at $496K in Q1 2026.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.